We can't talk healthcare
without talking about drug prices

Which is why our mission is to make innovative medicines available at radically lower prices.

At EQRx, we’re passionate about lowering the cost of new medicines.

See how we are raising awareness of financial toxicity and working to make
innovative new medicines available at radically lower costs.

EQRx stand for...

It all starts with our name.

The EQ in EQRx stands for a lot of things. But at its heart, our name stands for our societal contract to bring the best of today’s innovation to patients at radically lower prices.

Watch the Video Series:

Lowering Costs

EQRx’s radically lower cost medicines could dramatically increase global access for cancer patients and tackle the growing cost burden that befalls them.

Lowering costs

Innovative Medicines

We’ve already made significant progress toward our mission to make innovative medicines available at radically lower prices—starting with two potential therapies in lung cancer.

Read the aumolertinib results Read the sugemalimab results
Innovative Medicines

Unlikely Partnerships

Our radically new model brings together every aspect of the healthcare system through non-traditional partnerships that bring a new level of transparency & collaboration.

Innovative Medicines

Join us

In #remakingmedicine

Explore the data.

We’re starting in lung cancer with two innovative therapies that have now published Phase 3 clinical trial results.


Our Phase 3 Trial data of aumolertinib in first-line treatment of patients with stage III or IV non-small cell lung cancer (NSCLC) with the most common types of EGFR mutations presented at ASCO 2021

Read the results announcement


Our Phase 3 data of sugemalimab, an anti-PD-L1 antibody, in stage III non-small cell lung cancer (NSCLC)

Read the results announcement

Updated data from Phase 3 study of sugemalimab in Stage IV NSCLC presented at WCLC 2021

Read the results announcement

Results from Stage III and Stage IV studies suggest sugemalimab is a promising potential treatment option in a broad range of NSCLC patients at ESMO 2021

Read the results announcement